Humoral Immunity After mRNA SARS-CoV-2 Vaccination in Allogeneic HCT Recipients-Room for Improvement and Much to Learn
JAMA Netw Open
.
2021 Sep 1;4(9):e2127454.
doi: 10.1001/jamanetworkopen.2021.27454.
Author
Joshua A Hill
1
2
Affiliations
1
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2
Division of Allergy and Infectious Diseases, University of Washington, Seattle.
PMID:
34519771
DOI:
10.1001/jamanetworkopen.2021.27454
No abstract available
Publication types
Comment
MeSH terms
COVID-19 Vaccines
COVID-19*
Hematopoietic Stem Cell Transplantation*
Humans
Immunity, Humoral
RNA, Messenger
SARS-CoV-2
Vaccination
Substances
COVID-19 Vaccines
RNA, Messenger